Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of the ORBCEL-C therapy (MSCs derived from umbilical cord tissue) in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19

Next Previous
Trial Profile

Safety of the ORBCEL-C therapy (MSCs derived from umbilical cord tissue) in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orbcel-C (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Therapeutic Use
  • Acronyms REALIST COVID-19

Most Recent Events

  • 14 Apr 2020 New trial record
  • 07 Apr 2020 Accordding to a Queens University media release, this study is funded by the Health and Social Care Research & Development Division and the Wellcome Trust, sponsored by the Belfast Health and Social Care Trust and supported by the NI Clinical Trials Unit, the NIHR Clinical Research Network and the Northern Ireland Clinical Research Network.
  • 07 Apr 2020 Accordding to a Queens University media release, first patient has now been recruited with plans to recruit at least 60 patients throughout the COVID-19 pandemic at multiple sites across the UK including Belfast, Birmingham and London.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top